
APGE
Healthcare · Biotechnology · $10.22B market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2026
EPS trend, 90 days to now · -7.1% over 90 days · 30-day revisions 2 up, 3 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 10, 2026 | Before the open | -1.10 | -1.14 | -3.6% |
| May 11, 2026 | Before the open | -1.13 | -1.06 | +6.2% |
| Mar 10, 2026 | Time not confirmed | -0.62 | -1.03 | -66.1% |
| Nov 10, 2025 | Before the open | -1.15 | -1.11 | +3.5% |
| Aug 11, 2025 | Before the open | -1.05 | -1.13 | -7.6% |
| May 12, 2025 | Before the open | -1.19 | -0.95 | +20.2% |
| Mar 3, 2025 | Time not confirmed | -0.62 | -1.18 | -90.3% |
| Nov 12, 2024 | Before the open | -0.74 | -0.86 | -16.2% |
| Aug 12, 2024 | Before the open | -0.55 | -0.60 | -9.1% |
| May 13, 2024 | Before the open | -0.65 | -0.64 | +1.5% |
| Mar 5, 2024 | Before the open | -0.49 | -0.32 | +34.7% |
| Nov 13, 2023 | Before the open | -0.42 | -0.51 | -21.4% |
| Aug 28, 2023 | Before the open | -1.70 |
Apogee Therapeutics, Inc. develops and commercializes biologic therapies for immunological and inflammatory (I&I) diseases for patients and caregivers. The company's pipeline includes products, such as ZUMILOKIBART (APG777), a monoclonal antibody for atopic dermatitis, asthma, and eosinophilic esophagitis; APG990, a monoclonal antibody targeting OX40L; APG808, an antibody targeting IL-4Ra for chronic obstructive…
| -3.78 |
| -122.4% |
| May 31, 2023 | Time not confirmed | — | -2.38 | — |